1. Introduction
===============

Our VIth International Conference attracted over 800 participants. The meeting opened with an introductory day designed to provide background information on a wide variety of topics---from basic immunology, immune regulation and tolerance, to neurovirology, immunogenetics and inflammation, and including neuroendocrinology, neuronal development and imaging. Each of the four subsequent days had a main theme, which was presented first in the plenary sessions, added into one of the symposia, and then let rip during the afternoon workshops. These themes were chosen in addition to neurodegeneration and neurovirology, to the more conventional topics of antibody-mediated diseases and neuroinflammation. This report represents a sampling of the varied scientific fare on offer.

2. The first ISNI lecture
=========================

Cedric Raine (New York) treated us to a tour de force presentation on the Oligodendrocyte Enigma in Multiple Sclerosis. These cells produce the myelin whose ensheathing of axons enables rapid, repeated nerve transmission, and which is destroyed in Multiple Sclerosis (MS). Oligodendrocytes are susceptible to a variety of degenerative stimuli, including T cell cytolytic, apoptotic, bystander and excitotoxic mechanisms, and they have poor regenerative capacity. Because individual oligodendrocytes ensheath multiple axons, loss of a single oligodendrocyte may result in a MRI-definable lesion and loss of a few or many oligodendrocytes generates the classical MS plaque. Dr. Raine reviewed an impressive body of evidence for and against different mechanisms of oligodendrocyte killing, in particular commenting on the sparseness of evidence for Fas- or microglia/macrophage-mediated phagocytic killing. By contrast, CD68^+^ macrophages express glutaminase in MS lesions, and oligodendrocytes normally express but downregulate the glutamate-catabolizing enzymes GS and GDH. Levels of the glutamate transporter EAAT-2 were reduced in plaque-adjacent normal-appearing white matter. Taken together, these findings make a case for glutamate as a critical mechanism for both axonal and oligodendrocyte damage in MS. The role of astrocytes and the Notch/Jagged receptor/ligand pair as potential regulators of oligodendrocyte repair was also discussed. The lecture was followed by a presentation to Dr. Raine, who stepped down after 14 years as president of the ISNI. His erudite and comprehensive exploration of the oligodendrocyte was a fine flourish from a valued friend and colleague.

3. What is required for initiation of immune response in the CNS?
=================================================================

The role of dendritic and microglial cells in the initiation of immune responses in the CNS was very elegantly summarized by Aloisi (Rome), who covered recent data (from her lab and others) on dendritic cells (DC). The contribution of these antigen-presenting cells to CNS immunity has recently become apparent. De Vos (Rotterdam) added complementary data from primates, where CD83-expressing DC loaded with myelin lipids and proteins were identified in draining cervical lymph nodes of marmosets with end-stage EAE. These DC were in contact with T cells. Such observations reinforce previous reports that antigen may be transported from inflammatory sites in the CNS for presentation to the peripheral immune system. This is an important issue in elucidation of the etiology of MS and particularly of the generation of new waves of T cell specificities (epitope spreading).

Carson (La Jolla) showed that intracerebral administration of peptide-loaded DC in a model of molecular mimicry exacerbated CD8^+^ T cell responses to LCMV NP-expressing oligodendrocytes, without inducing either CD4^+^ T cell infiltration or demyelination. In light of the stimulating plenary presentation by Schwartz (Rehovot) on protective roles for myelin-reactive T cells, this kind of observation provokes questions whether host-protective and pathologic responses may be driven by different antigen-presenting cells in the CNS.

Spontaneous onset of demyelinating disease in older mice that express a CD86/B7.2 transgene was described by Zehntner (Montreal). These animals express CD86 in microglia and microglia-like cells in spinal roots. A mixed central/peripheral disease resulted from this expression of B7.2 on nervous system myeloid cells. This appears to be a situation where costimulator upregulation is sufficient for autoimmunity, although it was noted that peripheral T cells, which also express B7.2 in these mice, were constitutively of the memory-effector phenotype. Disease in these mice may serve as a model for infectious etiologies. Memory/effector phenotype IFNγ-secreting CD8^+^ T cells featured prominently, outnumbering CD4^+^ T cells in inflamed tissues.

Chitnis (Boston) described how the TNF/TNFR family members OX40 and OX40L can substitute, in the absence of the conventional CD28/B7 costimulatory pathway. Thus, EAE can be induced in CD28-deficient mice and anti-OX40L antibody can prevent this. This illustrates a multilayered 'failsafe' hierarchy of regulatory control of the T cell response that plays an important role in control of CNS disease. As a counterpoint to disease-promoting roles for CD28 ligands, Jabs (Boston) described a disease-enhancing role of ICOS-blockade in EAE in B7-deficient mice. This likely reflects a preferential role for ICOS in costimulating Th2 effector responses.

Howard (Chicago) and Laman (Rotterdam) described studies of the role of costimulation in directing epiptope spreading in EAE. CD40 blocking reagents were used to dissect the role of CD40 in EAE in mice (Howard) and marmosets (Laman). Interestingly, additional to its effects on T cell epitope spreading, broadening of the antibody response, normally a feature of EAE in marmosets, was prevented when animals were treated with CD40-blocking reagents.

Becher (Hanover, NH) described data from bone marrow chimeric mice in which MOG-induced EAE was modulated by reconstitution of CD40-deficient mice by wild-type bone marrow. The data indicate a role for CD40--CD40L(CD154) interactions within the CNS in control of disease. Likely candidate cells participating in these interactions include parenchymal microglia.

Heterogeneity in microglial response was discussed by Perry (Southampton), who described his lab\'s analyses of prion disease in mice. In this model, despite morphological changes associated with reactivity, microglia do not appear to express the usual inflammatory mediators (TNFα, IL1β, IL-6, or iNOS), and may instead express TGFβ and PGE2. Differential CNS regional expression of novel genes was identified in a screen for genes whose expression are reduced upon microglial activation (poster by Schmid, La Jolla). Signaling by CD200/OX2 for microglial quiescence was described by Sedgwick (Palo Alto). Mice deficient in OX2 showed enhanced or accelerated microglial responses to injury and inflammation.

4. CD8 T cells and anti-viral/autoimmune responses in CNS
=========================================================

The cytotoxic CD8^+^ T cell made quite a resurgence at this meeting. It has often been overlooked that CD8^+^ T cells are as frequent as if not more frequent than CD4^+^ T cells in multiple sclerosis lesions. Lassmann (Vienna) reviewed recent data showing not only that CD8s outnumbered CD4s in MS, but that when CDR3 spectratyping was used to determine their clonal heterogeneity, the CD8s were clearly more homogeneous than the CD4s. Individual cells were picked from peri-plaque infiltrates, and the data suggest strongly that the CD8s were engaged in an antigen-specific response. Consistent with this, MHC I was detected on cells identified as oligodendrocytes and neurons, as well as on endothelial and glial cells. CD8^+^ T cells expressed granzymes, which were implicated in axonal damage.

Trapp (Cleveland) showed characteristic onion bulb pathology of transected axons in secondary progressive MS brain. In SP-MS, 68% of axons are lost in spinal cord, when corrected for tissue volume. One caution to the CD8s day out was his claim that CD8 staining also detected macrophages in MS brain.

Neumann (Goettingen) provided fascinating evidence of the power of CD8^+^ T cells to wreak damage on cells in the CNS. Co-culture of isolated dorsal root ganglion neurons that were induced to express MHC I, with activated cytotoxic CD8^+^ T cells, resulted not only in neuronal death, measured by Ca^2+^ responses, but in some cases, when neurons were pulsed with the peptide recognized by CTLs, in what appeared to be actual transection of axon-like processes. Confocal microscopy showed apposition and even insertion of CD8 T cell processes to neurons. Involvement of perforin was excluded, and killing appeared to be via a Fas mechanism.

Diane Griffin (Baltimore) described IFNγ dependent clearance of alphavirus from rat brain. As a caveat to the above discussion, MHC I was rarely detectable on neurons in infected CNS, although easily detectable on other cells. It may be that the inducing stimulus of autoimmune infiltration is more potent than alphavirus. It was noteworthy that IFNγ-mediated virus clearance showed similar CNS regional preference as that for IFNγ-mediated MHC II induction in a separate study (McCluskey, L.P., Lampson, L.A., 2001. J. Neuroimmunol, 116--136) The possibility of a glial intermediate in virus clearance is attractive. The role of CD8^+^ T cells in virus clearance has been extensively described for rodent and primate models of CNS infection. The cellular dynamics of the immune response to Simian Virus in rhesus monkeys and to coronavirus in mice were described by Fox (La Jolla) and Bergmann (Los Angeles), respectively. Many of the 'usual suspects' featured (infiltration of the CNS, blood--brain barrier breakdown, upregulation of granzymes, perforin and Fas). Chronic antiviral immune responses that are protective against virus also contribute to neuropathology. These responses are maintained by continued recruitment and proliferation of CD8^+^ T cells at the site of response. Use of MHC I tetramers for visualization of such effector CD8^+^ T cells was shown by Williams (Boston) and McGavern (La Jolla), in elegant, confocal-visualized demonstrations of T cell interactions in infected tissue.

5. Metalloproteinases
=====================

This special symposium was chaired by Wee Yong (Calgary), who brought together a group of researchers to bring us up to date on this ever-expanding family of proteinases and their near-relatives, the ADAMs family (ADAM is an acronym for *A* *D*isintegrin *a*nd *M*etalloproteinase). This timely session brought us up to date on the complex roles that these enzymes play. Their ability to degrade extracellular matrix first brought them to the attention of the neuroimmunology community, as potential participants in immune cell invasion of the CNS. To this must now be added their action on multiple substrates, including cleavage of membrane-associated or -bound molecules to generate soluble mediators, viz. TNF.

Edwards (Norwich) reviewed the fast-expanding world of matrix metalloproteinases (MMPs) and ADAMs, and Yong presented work on the role of MMP-9 and MMP-12 in remyelination and CNS repair. Kieseier (Graz) reviewed the evidence that certain MMPs may be detrimental in MS and EAE, and considered whether inhibitors of metalloproteinases may be useful novel therapeutics for MS. Rosenberg (Albuquerque, NM) highlighted the roles that MMPs play in the disruption of blood--brain barrier integrity. Opdenakker (Leuwen) described the REGA model for autoimmunity and the role of MMP-9 or Gelatinase-B in regulating epitope presentation by the digestion of the extracellular matrix. The link between neutrophil-derived MMP-9 and chemokine regulation is particularly striking, and brings together threads from disparate sources to weave an interpretative fabric for MS. Woodroofe (Sheffield) presented recently-published and unpublished data that identify astrocytes and endothelial cells as sources of MMPs and ADAMs in inflamed human CNS. Expression of ADAMs by endothelia is reduced in inflammation, arguing for a reduction in soluble TNFα, amongst other molecules, possibly reflecting closer interaction between T cells and endothelia. Upregulation of ADAMs by astrocytes was speculated to reduce adhesion ligand expression through shedding, so affecting leukocyte traffic at the blood--brain barrier. Finally, Gveric (London) highlighted the roles that non-metalloproteinases, and in particular the serine proteinase plasmin, may play in tissue injury and recovery.

6. Clinical trials and correlates
=================================

Arnason (Chicago) reviewed contradictory and complex findings from trials of various therapies in MS. The surge in IFNγ production that accompanies initiation of treatment with IFNβ, Copaxone, Poly-IC and intravenous immunoglobulin is difficult to reconcile with the disease-exacerbating effects of IFNγ in MS reported 15 years ago by Panitch (Baltimore) and colleagues. In a separate workshop, Link (Stockholm) presented data for differential effects of IFNβ and glatiramer acetate (Cop-1) on expression of CD123 by MS DC in vitro. Nevertheless, both drugs increased CD86/B7.2 and the effects of combination in vitro therapy were more like those of IFNβ alone.

Weiner (Boston) discussed the role of IL-12 and IL-18 in regulating IFNγ production in MS and during cyclophosphamide therapy. Cyclophosphamide promotes the generation of CCR4^+^ T cells, which are implicated in Th2 responses, and this may account for its reduction of IFNγ levels in those young progressive patients with gadolinium-enhancing lesions, where it is most effective. Hohlfeld (Martinsried) gave us a comprehensive tour of surrogate cytokine markers for Copaxone therapy, which also affects the Th1/Th2 balance in MS.

The mysteries of intravenous immunoglobulin therapy were unveiled by Scolding (Cambridge). IV Ig therapy may be more effective in peripheral disease than disease in the CNS. This therapy may operate at a number of levels, including cytokine induction, reduction in complement levels, and promotion of remyelination and repair. Signaling through FcγRIII leads to inhibition of the phagocytic activity of macrophages/microglia.

7. Effector and regulatory cytokines
====================================

The interferons and their inducing cytokine, IL-12, were featured in a plenary symposium. Adorini (Milan) reviewed the role of IL-12 in directing inflammatory responses. He compared microglia to CD1 and astrocytes to B cells or DC2 in terms of their effects on T cell responses, consistent with the ability of microglia to produce IL-12, in contrast to astrocytes. The phagocytic history of macrophages/microglia ('you are what you eat...?') may be relevant, given that a diet of apoptotic cells induces expression of PGE2, TGFβ and PAF, but no inflammatory cytokines. Furthermore, the fact that IL-12-deficient NOD mice get diabetes, and that not all effects of IL-12 are mediated via IFNγ, introduced cautions to over-simplistic interpretations. The fact that Type I interferons may substitute for IL-12 in directing IFNγ production in humans was also noted. Vitamin D3 analogs inhibited IL-12 production by DC, and reduced IFNγ titers in serum and T cell proliferative responses to MOG. This identifies a potentially promising therapeutic approach for MS and other diseases.

Campbell (La Jolla) described a transgenic mouse model for the effect of Type I interferons in the CNS. GFAP promoter-driven expression of IFNα produced calcification around vessels, infiltration of CD4^+^ T cells and astrogliosis. This pathology mimics that seen in Cree encephalitis and Aicardi--Gouttieres Syndrome. The fact that Type I interferons, unlike IFNγ, are produced within the CNS, and that neuropsychiatric impairment has been noted consequent to therapy with Type I IFNs, calls to our attention the potential role for Type I interferons in CNS inflammatory pathology. Intriguingly, knockout of the primary IFN-receptor signal transducing mediator, STAT-1, exacerbated the phenotype of these mice. This identifies potential beneficial roles for STAT-1 signaling, distinct from STAT-1-independent signal transduction that promotes neurodegenerative pathology. Gene chip analyses will identify genes whose expression is modulated by STAT-1 signaling.

IFNγ was reviewed by Owens (Montreal). Potential immunomodulatory roles for this cytokine continue to emerge. Some of these may be mediated by the enzyme iNOS, and data were shown for inter-regulation between iNOS and TNFRI signaling in EAE. The fact that TNFRI is implicated in IL-12 responses provided a neat closing of the circle for this symposium topic. It is noteworthy that the only trial of IFNγ in MS, in which disease was exacerbated, has not been replicated in animal models. However, IFNγ is not so much beneficial to EAE, as had been suggested in another session, but rather re-directs disease away from a neutrophil-dominated pathology. Results presented by Martino (Milan) in another symposium also addressed this issue, showing that introduction of viral vectors that expressed IFNγ to the CNS by the ependymal route were protective rather than pro-inflammatory in EAE, inducing increased apoptosis of effector cells. By contrast, the fact that IFNγ potentiates glutamate excitotoxicity for neurons adds to the case for this cytokine as a mediator of pathology in MS (poster by Finsen, Odense).

8. Antibodies and disease
=========================

In the Dale McFarlin Lecture, John Newsom Davis (Oxford) described the now classic studies that demonstrated a pathogenic role for antibodies to acetylcholine receptor (AChR) in myasthenia gravis. Antibodies to another neuromuscular junction protein, MuSK, are found in a subset of patients, and those binding specifically to the fetal AChR in mothers of babies with a severe developmental condition. Myasthenia gravis is still one of the only autoimmune diseases in which the target antigens are known, and in which highly selective immunotherapies can be devised. Understanding the interaction between antigen-presenting cells and T cells is crucial (Davis, Stanford) and finding ways by which to target this interaction. This was an issue addressed in the Myasthenia Gravis Special Symposium: class II-peptide tetramers and monomers designed to identify and tolerise AChR-specific T cells, respectively, is one challenging way forward (Kishore, Oxford).

Antibodies seem also to be having a revival in Guillain--Barrés Syndrome (GBS). Jack Griffin (Baltimore) described detailed morphological studies that discriminate between cell-mediated demyelination and antibody-dependent axonal damage, with the latter probably more common in post-*Campylobacter jejuni* cases with ganglioside antibodies. The most prominent form of GBS in Europe and North America is Acute Inflammatory Demyelinating Neuropathy (AIDP), a demyelinating disease with variable degree of lymphocytic infiltration. Acute Motor Axonal Neuropathy (AMAN) is a non-demyelinating axonopathy that shows preferential loss of motor function. The AMAN pattern of GBS is associated with *C. jejuni* infection, and a molecular mimicry etiology is proposed. Dr. Griffin and his colleagues in China have studied an impressive cohort of patients through summer epidemics of infection-related disease. This disease shows ventral root degeneration with no inflammation and little demyelination. Macrophage recruitment to the periaxonal space is associated with anti-ganglioside (anti-GM1) antibodies and complement deposition, specifically at the nodes of Ranvier. The ventral root exit zone appears to be the site of access for autoantibodies. A population of microglial-like cells staining with the ED2 antibody are prominent in slice cultures of ventral roots, providing evidence for a non-blood-derived population of endoneurial cells that may play a role in these neuropathies.

In Rasmussen\'s encephalitis, the most severe form of epilepsy which often require treatment with hemispherectomy, some patients have antibodies to ds DNA, Cardiolipin and B2 glycoprotein, in addition to the anti-GluR3B antibodies which were previously described (Levite, Israel). Autoantibodies were also found in the healthy twins of patients with Rasmussen\'s, suggesting that autoimmunity can precede the epilepsy. Bermasconi (Italy) found antibodies to GluR3A and B not only in Rasmussen\'s encephalitis but also in patients with generalized epilepsy, with an association with severity. On the other hand, Bauer (Vienna) found CD8^+^/Gr B^+^ CTL in close apposition to neurons in biopsy studies, suggesting that the primary lesion is cytotoxic, leading secondarily to antibodies to GluR3 (and perhaps DNA, cardiolipin, etc.) with enhanced seizures. Whichever the primary mechanisms, the immune system seems to be involved because prolonged immunomodulatory therapy can reduce the need for surgery in this very aggressive condition (Hart, Liverpool). Antibodies to other ion channels were found in other epilepsy patients: anti-voltage-gated potassium channels in 5/22 patients, three of whom had other autoimmune conditions (Lang, Oxford), and in two patients with limbic encephalitis which includes seizures (Buckley, Oxford). In these cases, with circulating antibodies that are likely to cause neuronal hyperexcitability, immunotherapies may well be beneficial as suggested in preliminary reports.

New findings in other CNS disorders were also presented. Anti-streptolysin O titres were raised in the majority of Tourette\'s Syndrome (TS) patients (60% adults, 75% children), and antibodies to basal ganglia in patients by ELISA, by western blotting with a strong band at 60 kDa, and by indirect immunofluorescence, on the head of the caudate (Church, London). Antibodies to basal ganglia were also found in 95% of patients with acute Sydenham\'s Chorea (SC) compared to 13% of patients with rheumatic fever without SC and to 0% of healthy controls (Dale, London). These findings add further evidence to suggest overlap between TS and SC in pathophysiology as well as symptomatology. However, it is not yet clear whether these antibodies are pathogenic. For instance, some antibodies, usually those to intracellular targets, are markers for destruction of CNS tissue, but do not directly cause the disease. This occurs particularly in the presence of certain cancers, particularly small cell lung cancer, which can express a variety of neuronal antigens, many of which are involved in RNA processing and are of fundamental significance in development (Darnell, NY). Unfortunately, in these cases, the antibodies are not directly pathogenic, and immunotherapies are seldom effective.

Finally, Schenk (San Francisco) and Aguzzi (Switzerland) discussed how therapeutic immunization could be a potential treatment for human disorders associated with accumulation of amyloid or prion proteins, respectively. The recent data showing antibody-mediated clearance of amyloid plaques in the murine model of Alzheimer\'s (Schenk), is particularly exciting.

9. The neuroendocrine system
============================

One aspect, often neglected, is the three-way interaction between immune, endocrine and neurological systems, and the ways by which each can modulate the activity of the other two. The International Society for NeuroImmunomodulation held a special symposium to examine these topics. Of particular importance is the hypothalamic--pituitary--adrenal (HPA) axis and the stress response. Stimulation of the HPA axis results in the secretion of glucocorticoids and adrenocorticotrophic hormone (ACTH), which suppress the immune response, increased activation of the stress response predisposes to infection, whereas decreased activation predisposes to autoimmunity (Sternberg, Bethesda). When the HPA axis is hyporesponsive, susceptibility to EAE is increased, and in MS patients, plasma and cerebrospinal fluid (CSF) levels of cortisol are elevated and the responsivity of the HPA system is altered, leading to the activation of corticotropin-releasing hormone (CRH)-responsive neurons (Huitinga, Amsterdam). Psychological stress has been implicated in the onset and relapse of MS (Welsh, Texas). However, Jessop (Bristol) pointed out that there is no consistent relationship between the level of cortisone and extent of inflammation because many other compounds released during stress responses are important also.

Neurotransmitters have been shown to have effects on the immune system. Levite (Rehovot) suggested that the direct interaction of neurotransmitters with T cells could account for the many functions of T cells that cannot be explained by classical immunological signaling; lymphoid tissues are heavily innervated, and T cells express receptors for specific neurotransmitters. For example, whereas dopamine induces the adhesion of T cells to fibronectin through β1 integrins, substance P blocks the adhesion and activation of T cells (Levite, Rehovot). Maestroni (Locarno) spoke about the regulation of dendritic cell (DC) migration by the cytokine-mediated production of noradrenaline (NA) by the sympathetic nervous system. He suggested that different allergens induce expression of different cytokines, having differing effects on the production of NA and, thus, the activation of the adaptive immune response by Ag-presenting DCs. β-Adrenergic antagonists could be used to enhance oral-tolerance therapies for autoimmune disease by optimizing the cytokine milieu of the gut immune system in favor of anti-inflammatory cytokines (Heijnen, Utrecht).

10. Final comments
==================

Neuroimmunology is becoming more and more relevant to a wide-range of clinical disorders. The Edinburgh meeting was a tremendous success in terms of the breadth of research that was brought together and the mix of disciplines and interests that converged on Neuroimmunology. This review highlights only some of the many aspects discussed, and we apologize to those whose work we have not included. Different perspectives are provided in Trends in Immunology (Minton, K., 2001. Immune mechanisms in neurological disorders: protective or destructive? Trends in Immunology 22, 655--657) and in Advances in Clinical Neuroscience and Rehabitation (Coles, A. ACNR 1/5, 27--28).
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